1. | nlove21265 | |
2. | xuxaparkus | |
3. | eddenusa | |
4. | dancebunch | |
5. | snoruiz |
1. | nlove21265 | |
2. | xuxaparkus | |
3. | eddenusa | |
4. | dancebunch | |
5. | snoruiz |
1. | xuxaparkus 06/03/2018 Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer |
2. | nlove21265 02/08/2018 Beats EPS loss estimates by $0.10. Misses on revenues. |
3. | eddenusa 04/25/2018 Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (mBC) at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting |
4. | snoruiz 05/21/2018 Submits a BLA |
5. | xuxaparkus 05/17/2018 Reports 'positive' data for sacituzumab govitecan, its metastatic breast cancer drug |